Literature DB >> 35294114

Cause-Specific Mortality in Patients with Gout in the United States Veteran's Health Administration: A Matched Cohort Study.

Lindsay N Helget1,2, Bryant R England1,2, Punyasha Roul1,2, Harlan Sayles2,3, Alison D Petro1,2, Tuhina Neogi4, James R O'Dell1,2, Ted R Mikuls1,2.   

Abstract

OBJECTIVE: Compare all-cause and cause-specific mortality risk between gout and non-gout patients in the Veteran's Health Administration (VHA).
METHODS: We performed a matched cohort study, identifying patients with gout in the VHA from 1/1999-9/2015 based on the presence of ≥2 ICD-9 codes for gout (274.X). Gout patients were matched up to 1:10 on birth year, sex, and year of VHA enrollment with non-gout patients and followed until death or end-of-study (12/2017). Cause of death was obtained from the National Death Index. Associations of gout with all-cause and cause-specific mortality were examined using multivariable Cox regression.
RESULTS: Gout (n=559,243) and matched non-gout controls (n=5,428,760) had a mean age of 67 years and were 99% male. There were 246,291 deaths over 4,250,371 patient-years in gout patients and 2,000,000 deaths over 40,441,353 patient-years of follow-up in controls. After matching, gout patients had an increased risk of death (HR 1.09; 95% CI 1.08-1.09) which was no longer present after adjusting for comorbidities (HR 0.98; 95% CI 0.97-0.98). The strongest association of gout with cause-specific mortality was observed with genitourinary conditions (HR 1.50; 95% CI 1.47-1.54). Gout patients were at lower risk of death related to neurologic (e.g., Alzheimer's, Parkinson's) (HR 0.63; 95% CI 0.62-0.65) and mental health (HR 0.66; 95% CI 0.65-0.68) conditions.
CONCLUSION: A higher risk of death among gout patients in the VHA was related to comorbidity burden. While deaths attributable to neurologic and mental health conditions were less frequent among gout patients, genitourinary conditions were the most overrepresented causes of death. This article is protected by copyright. All rights reserved.

Entities:  

Year:  2022        PMID: 35294114      PMCID: PMC9477976          DOI: 10.1002/acr.24881

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   5.178


  48 in total

1.  The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012.

Authors:  Sharan K Rai; J Antonio Aviña-Zubieta; Natalie McCormick; Mary A De Vera; Kam Shojania; Eric C Sayre; Hyon K Choi
Journal:  Semin Arthritis Rheum       Date:  2016-08-17       Impact factor: 5.532

2.  Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism.

Authors:  M Mazzali; J Hughes; Y G Kim; J A Jefferson; D H Kang; K L Gordon; H Y Lan; S Kivlighn; R J Johnson
Journal:  Hypertension       Date:  2001-11       Impact factor: 10.190

3.  Uric acid therapy improves the outcomes of stroke patients treated with intravenous tissue plasminogen activator and mechanical thrombectomy.

Authors:  Ángel Chamorro; Sergio Amaro; Mar Castellanos; Meritxell Gomis; Xabier Urra; Jordi Blasco; Juan F Arenillas; Luis S Román; Roberto Muñoz; Juan Macho; David Cánovas; Joan Marti-Fabregas; Enrique C Leira; Anna M Planas
Journal:  Int J Stroke       Date:  2016-12-20       Impact factor: 5.266

4.  Serum Uric Acid and Its Association with Longitudinal Cognitive Change Among Urban Adults.

Authors:  May A Beydoun; Jose-Atilio Canas; Gregory A Dore; Hind A Beydoun; Ola S Rostant; Marie T Fanelli-Kuczmarski; Michele K Evans; Alan B Zonderman
Journal:  J Alzheimers Dis       Date:  2016-04-21       Impact factor: 4.472

5.  Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016.

Authors:  Michael Chen-Xu; Chio Yokose; Sharan K Rai; Michael H Pillinger; Hyon K Choi
Journal:  Arthritis Rheumatol       Date:  2019-04-15       Impact factor: 10.995

6.  Content and construct validity of the Rheumatic Diseases Comorbidity Index in patients with gout.

Authors:  Bart Spaetgens; José M A Wijnands; Caroline van Durme; Annelies Boonen
Journal:  Rheumatology (Oxford)       Date:  2015-04-17       Impact factor: 7.580

Review 7.  Adipose tissue, obesity and non-alcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Jannis Kountouras; Christos S Mantzoros
Journal:  Minerva Endocrinol       Date:  2016-10-06       Impact factor: 2.184

8.  Prevalence and incidence of gout in Korea: data from the national health claims database 2007-2015.

Authors:  Ji-Won Kim; Sang Gyu Kwak; Hwajeong Lee; Seong-Kyu Kim; Jung-Yoon Choe; Sung-Hoon Park
Journal:  Rheumatol Int       Date:  2017-07-04       Impact factor: 2.631

9.  Posing the question again: does chronic uric acid nephropathy exist?

Authors:  Orson W Moe
Journal:  J Am Soc Nephrol       Date:  2009-09-03       Impact factor: 10.121

10.  Serum uric acid levels are associated with obesity but not cardio-cerebrovascular events in Chinese inpatients with type 2 diabetes.

Authors:  Ming-Yun Chen; Cui-Chun Zhao; Ting-Ting Li; Yue Zhu; Tian-Pei Yu; Yu-Qian Bao; Lian-Xi Li; Wei-Ping Jia
Journal:  Sci Rep       Date:  2017-01-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.